International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 3 , ISSUE 2 ( May-August, 2012 ) > List of Articles

REVIEW ARTICLE

Applications of Cell-Free Fetal DNA in Maternal Serum

Saeid Ghorbian

Citation Information : Ghorbian S. Applications of Cell-Free Fetal DNA in Maternal Serum. Int J Infertil Fetal Med 2012; 3 (2):33-39.

DOI: 10.5005/jp-journals-10016-1038

Published Online: 00-08-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Ghorbian S. Applications of Cell-Free Fetal DNA in Maternal Serum. Int J Infertility Fetal Med 2012;3(2):33-39.


PDF Share
  1. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-87.
  2. Practical and theoretical implications of fetal-maternal lymphocyte transfer. Lancet 1969;1119-22.
  3. Procedure-related complications of amniocentesis and chorionic villous sampling: A systematic review. Obstet Gynecol 2007;110:687-94.
  4. PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies. Am J Hum Genet 1997;61:822-29.
  5. Free fetal DNA in maternal plasma in anembryonic pregnancies: Confirmation that the origin is the trophoblast. Prenat Diagn 2007;27: 415-18.
  6. Evaluation of bidirectional transfer of plasma DNA through placenta. Hum Genet 2003;113:307-10.
  7. Placental volume, as measured by 3-dimensional sonography and levels of maternal plasma cell-free fetal DNA. Am J Obstet Gynecol 2005;193:496-500.
  8. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768-75.
  9. Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin Chem 2008;54:1664-72.
  10. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 2004;50:88-92.
  11. Early detection of cell-free fetal DNA in maternal plasma. Early Hum Dev 2007;83:563-66.
  12. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. Clin Chem 2005;51:312-20.
  13. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184-88.
  14. Cell-free fetal DNA levels in maternal plasma after elective first-trimester termination of pregnancy. Fertil Steril 2004;81:638-44.
  15. Fetal DNA in maternal plasma: Biology and diagnostic applications. Clin Chem 2000;46:1903-06.
  16. Chorionic villus sampling and amniocentesis. Curr Opin Obstet Gynecol 2005;17:197-201.
  17. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999;19:505-12.
  18. Human cytotrophoblasts acquire aneuploidies as they differentiate to an invasive phenotype. Dev Biol 2005;279:420-32.
  19. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
  20. Adhesive and degradative properties of human placental cytotrophoblast cells in vitro. J Cell Biol 1989;109:891-902.
  21. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem 2000;46:301-02.
  22. Trophoblastic oxidative stress and the release of cellfree feto-placental DNA. Am J Pathol 2006;169:400-04.
  23. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update 2009;15:139-51.
  24. Immunological aspects of circulating DNA. Ann NY Acad Sci 2006;1075:34-39.
  25. Circulating fetal DNA: Its origin and diagnostic potential—a review. Placenta 2004;25(Suppl A):S93-101.
  26. Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of preeclampsia. Am J Obstet Gynecol 2004;191:515-20.
  27. Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset preeclampsia. Clin Chem 2005;51:1730-33.
  28. Minimal alteration in the ratio of circulatory fetal DNA to fetal corticotropinreleasing hormone mRNA level in preeclampsia. Fetal Diagn Ther 2006;21:246-49.
  29. Maternal plasma fetal DNA as a marker for preterm labour. Lancet 1998;352:1904-05.
  30. Sex-determining region Y levels in maternal plasma: Evaluation in abnormal pregnancy. J Obstet Gynaecol Res 2004;30:148-54.
  31. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta 2006;363: 187-96.
  32. New strategy for prenatal diagnosis of X-linked disorders. N Engl J Med 2002; 346:1502.
  33. Antenatal determination of fetal RhD-blood type based on fetal DNA in plasma from the RhD-negative mother—secondary publication. Ugeskr Laeger 2006;168:2568-70.
  34. Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. Transfusion 2005;45: 1473-80.
  35. Noninvasive antenatal RhD typing. Trarsfus Clin Biol 2006;13:53-57.
  36. Prenatal exclusion of beta-thalassaemia major by examination of maternal plasma. Lancet 2002;360:998-1000.
  37. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA 2005;293:843-49.
  38. Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: A feasibility study. Clin Chem 2002;48:778-80.
  39. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet 2000;356:1170.
  40. Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem 2005;51:1598-1604.
  41. Noninvasive genotyping of 9 Y-chromosome specific STR loci using circulatory fetal DNA in maternal plasma by multiplex PCR. Prenat Diagn 2006;26: 362-68.
  42. Quantitation of fetal DNA in maternal serum during the first trimester of pregnancy by the use of a DAZ repetitive probe. Mol Hum Reprod 2006;12:587-91.
  43. Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy. Prenat Diagn 2005;25:1111-16.
  44. Identification of fetal gender in maternal blood is a helpful tool in the prenatal diagnosis of haemophilia. Haemophilia 2006;12:417-22.
  45. Ethical aspects arising from non-invasive fetal diagnosis. Semin Fetal Neonatal Med 2008;13:103-08.
  46. Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstet Gynecol 2001;98:374-78.
  47. Prenatal exclusion of recessively inherited disorders: Should maternal plasma analysis precede invasive techniques? Clin Chem 2002;48:689-90.
  48. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:385-87.
  49. Accuracy of fetal gender determination by analysis of DNA in maternal plasma. Clin Chem 2001;47:1856-58.
  50. Successful diagnosis of fetal gender using conventional PCR analysis of maternal serum. Clin Chem 2001;47:41-46.
  51. Kinetics of SRY gene appearance in maternal serum: Detection by real time PCR in early pregnancy after assisted reproductive technique. Hum Reprod 2003;18:1733-36.
  52. Clin Chem 2004;50:678-79.
  53. Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy. Prenat Diagn 2005;25:1111-16.
  54. Non-invasive fetal sex determination using real-time PCR. J Matern Fetal Neonatal Med 2006;19:337-42.
  55. Foetal sex determination in maternal blood from the seventh week of gestation and its role in diagnosing haemophilia in the foetuses of female carriers. Haemophilia 2008;14:593-98.
  56. Fetal sex determination using circulating cellfree fetal DNA (ccffDNA) at 11 to 13 weeks of gestation. Prenat Diagn 2010;30:918-23.
  57. Noninvasive fetal sex determination using cell-free fetal DNA A systematic review and meta-analysis. JAMA 2011;306:627-36.
  58. Recent advances in non-invasive prenatal DNA diagnosis through analysis of maternal blood. J Obstet Gynaecol Res 2007;33: 747-64.
  59. Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. Transfusion 2005;45: 1473-80.
  60. Fetal rhd genotyping from maternal plasma in a population with a highly diverse ethnic background. Rev Assoc Med Bras 2006;52: 232-35.
  61. Noninvasive fetal RHD genotyping from maternal plasma. Use of a new developed free DNA fetal kit RhD. Transfus Clin Biol 2007;14: 572-77.
  62. Routine fetal RHD genotyping with maternal plasma: A four-year experience in Belgium. Transfusion 2008;48: 373-81.
  63. Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med 2010;48:1121-26.
  64. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 2011;31: 802-08.
  65. A multiplex PCR for non-invasive fetal RHD genotyping using cell-free fetal DNA. In Vivo 2011;25:411-17.
  66. Prediction of fetal D status from maternal plasma: Introduction of a new noninvasive fetal RhD genotyping service. Transfusion 2002;42: 1079-85.
  67. Non-invasive prenatal detection of achondroplasia in sizefractionated cell-free DNA by MALDI-TOF MS assay. Prenat Diagn 2007;27:11-17.
  68. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet 2000;356:1170.
  69. Huntington disease-unaffected fetus diagnosed from maternal plasma using QF-PCR. Prenat Diagn 2003;23:232-34.
  70. Early Huntington disease prenatal diagnosis by maternal semiquantitative fluorescent-PCR. Neurol 2003;60:1214-15.
  71. Prenatal diagnosis of Huntington disease in maternal plasma: Direct and indirect study. Eur J Neurol 2008;15:1338-44.
  72. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem 2000;46:301-02.
  73. Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: A feasibility study. Clin Chem 2002;48:778-80.
  74. Haemoglobinopathies in pregnancy. Obstet Gynecol 2005;7:149-57.
  75. Improvement in sensitivity of allele-specific PCR facilitates reliable noninvasive prenatal detection of cystic fibrosis. Clin Chem 2004;50: 694-01.
  76. Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood 2011;31:117.
  77. Non-invasive prenatal diagnosis using cell-free fetal DNA technology: Applications and implications. Publ Heal Genom 2010;13:246-55.
  78. To err (meiotically) is human: The genesis of human aneuploidy. Nat Rev Genet 2001;2:280-91.
  79. Observations on an ethnic classification of idiots. 1866 Ment Retard 1995;33:54-56.
  80. Invasive prenatal diagnostic techniques. Semin Perinatol 2005;29:401-04.
  81. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem 1999;45:1747-51.
  82. Down syndrome and cell-free fetal DNA in archived maternal serum. Am J Obstet Gynecol 2002;187:1217-21.
  83. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci USA 2007;104:13116-21.
  84. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validity. BMJ 2011;342:c7401.
  85. Forensic issues in Down syndrome fatalities. J Forensic Leg Med 2007;14:475-81.
  86. Maternal serum cell free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum Genet 2003;112:204-08.
  87. Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. Clin Chem 2006;52:2194-02.
  88. STR primer concordance study. Forensic Sci Int 2001;124:47-54.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.